BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 35409064)

  • 21. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
    Tang D; Kroemer G; Kang R
    Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.
    Paolo M; Assunta S; Antonio R; Claudia SP; Anna BM; Clorinda S; Francesca C; Fortunato C; Cesare G
    Rev Recent Clin Trials; 2013 Jun; 8(2):93-100. PubMed ID: 24063423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS: A Druggable Target in Colon Cancer Patients.
    Negri F; Bottarelli L; de'Angelis GL; Gnetti L
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview.
    Tokumaru Y; Takabe K; Yoshida K; Akao Y
    Cancer Sci; 2020 Apr; 111(4):1076-1083. PubMed ID: 32077199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ras and exosome signaling.
    Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
    Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting RAS in pediatric cancer: is it becoming a reality?
    Vaseva AV; Yohe ME
    Curr Opin Pediatr; 2020 Feb; 32(1):48-56. PubMed ID: 31815779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.
    Chen H; Smaill JB; Liu T; Ding K; Lu X
    J Med Chem; 2020 Dec; 63(23):14404-14424. PubMed ID: 33225706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small molecule inhibitors of RAS proteins with oncogenic mutations.
    Orgován Z; Keserű GM
    Cancer Metastasis Rev; 2020 Dec; 39(4):1107-1126. PubMed ID: 32770300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biology, pathology, and therapeutic targeting of RAS.
    Rhett JM; Khan I; O'Bryan JP
    Adv Cancer Res; 2020; 148():69-146. PubMed ID: 32723567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.
    Haider K; Sharma A; Yar MS; Yakkala PA; Shafi S; Kamal A
    Expert Opin Drug Discov; 2022 Mar; 17(3):247-257. PubMed ID: 35084268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
    Hood FE; Sahraoui YM; Jenkins RE; Prior IA
    Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KRAS and BRAF: drug targets and predictive biomarkers.
    Vakiani E; Solit DB
    J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dueling KRAS
    Cancer Discov; 2020 Jan; 10(1):10. PubMed ID: 31822538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Climbing RAS, the everest of oncogenes.
    Russo M; Di Nicolantonio F; Bardelli A
    Cancer Discov; 2014 Jan; 4(1):19-21. PubMed ID: 24402942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the RAS-dependent chemoresistance: The Warburg connection.
    Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
    Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Past, Present, and Future of Targeting Ras for Cancer Therapies.
    Tan Z; Zhang S
    Mini Rev Med Chem; 2016; 16(5):345-57. PubMed ID: 26423695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.